Blueprint Medicines Corp  

(Public, NASDAQ:BPMC)   Watch this stock  
Find more results for BPMC
-1.11 (-1.34%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 80.75 - 84.10
52 week 32.43 - 92.00
Open 81.94
Vol / Avg. 0.00/303,467.00
Mkt cap 3.49B
P/E     -
Div/yield     -
EPS -3.42
Shares 42.88M
Beta     -
Inst. own 108%
Mar 13, 2018
Blueprint Medicines Corp at Cowen Health care Conference - 11:20AM EDT - Add to calendar
Feb 21, 2018
Q4 2017 Blueprint Medicines Corp Earnings Release - 9:30AM EST - Add to calendar
Feb 21, 2018
Q4 2017 Blueprint Medicines Corp Earnings Call - 8:30AM EST - Add to calendar
Dec 11, 2017
Blueprint Medicines Corp to Discuss Updated BLU-285 Clinical Data Presented at ASH Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -467.32% -261.04%
Operating margin -478.56% -261.33%
EBITD margin - -255.64%
Return on average assets -34.97% -31.40%
Return on average equity -42.28% -40.61%
Employees 133 -
CDP Score - -


45 Sidney St
CAMBRIDGE, MA 02139-4133
United States - Map
+1-617-3747580 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Officers and directors

Daniel S. Lynch Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Jeffrey W. Albers President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Tracey L. Mccain executive vice president and chief legal
Age: 49
Bio & Compensation  - Reuters
Marion Dorsch Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Michael Landsittel Vice President, Finance
Age: 45
Bio & Compensation  - Reuters
Anthony L. Boral M.D. Ph.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Kathryn Haviland Chief Business Officer
Age: 41
Bio & Compensation  - Reuters
Alexis Borisy Director
Age: 45
Bio & Compensation  - Reuters
Lonnel Coats Independent Director
Age: 52
Bio & Compensation  - Reuters
George D. Demetri Independent Director
Age: 60
Bio & Compensation  - Reuters